Refex Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 18, 2025, 6:26 pm

Competitors of Refex Industries Ltd

All Competitor Stocks of Refex Industries Ltd

Quarterly Result

Last Updated: August 20, 2025, 4:30 am

Below is a detailed analysis of the quarterly data for Refex Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 365.00 Cr.. The value appears to be declining and may need further review. It has decreased from 611.00 Cr. (Mar 2025) to 365.00 Cr., marking a decrease of 246.00 Cr..
• For Expenses, as of Jun 2025, the value is 325.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 548.00 Cr. (Mar 2025) to 325.00 Cr., marking a decrease of 223.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 40.00 Cr.. The value appears to be declining and may need further review. It has decreased from 64.00 Cr. (Mar 2025) to 40.00 Cr., marking a decrease of 24.00 Cr..
• For OPM %, as of Jun 2025, the value is 11.00%. The value appears strong and on an upward trend. It has increased from 10.00% (Mar 2025) to 11.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 5.00 Cr..
• For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
• For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 41.00 Cr.. The value appears to be declining and may need further review. It has decreased from 72.00 Cr. (Mar 2025) to 41.00 Cr., marking a decrease of 31.00 Cr..
• For Tax %, as of Jun 2025, the value is 20.00%. The value appears to be improving (decreasing) as expected. It has decreased from 21.00% (Mar 2025) to 20.00%, marking a decrease of 1.00%.
• For Net Profit, as of Jun 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Mar 2025) to 33.00 Cr., marking a decrease of 24.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.55. The value appears to be declining and may need further review. It has decreased from 4.42 (Mar 2025) to 2.55, marking a decrease of 1.87.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:34 am

Growth

Last Updated: September 5, 2025, 1:00 pm

Balance Sheet

Last Updated: May 13, 2025, 2:50 pm

Below is a detailed analysis of the balance sheet data for Refex Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Mar 2024) to 26.00 Cr., marking an increase of 3.00 Cr..
• For Reserves, as of Mar 2025, the value is 1,224.00 Cr.. The value appears strong and on an upward trend. It has increased from 450.00 Cr. (Mar 2024) to 1,224.00 Cr., marking an increase of 774.00 Cr..
• For Borrowings, as of Mar 2025, the value is 158.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 161.00 Cr. (Mar 2024) to 158.00 Cr., marking a decrease of 3.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 272.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 114.00 Cr. (Mar 2024) to 272.00 Cr., marking an increase of 158.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,681.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 748.00 Cr. (Mar 2024) to 1,681.00 Cr., marking an increase of 933.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 199.00 Cr.. The value appears strong and on an upward trend. It has increased from 144.00 Cr. (Mar 2024) to 199.00 Cr., marking an increase of 55.00 Cr..
• For CWIP, as of Mar 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 9.00 Cr. (Mar 2024) to 6.00 Cr., marking a decrease of 3.00 Cr..
• For Investments, as of Mar 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2024) to 114.00 Cr., marking an increase of 33.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,362.00 Cr.. The value appears strong and on an upward trend. It has increased from 514.00 Cr. (Mar 2024) to 1,362.00 Cr., marking an increase of 848.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,681.00 Cr.. The value appears strong and on an upward trend. It has increased from 748.00 Cr. (Mar 2024) to 1,681.00 Cr., marking an increase of 933.00 Cr..

Notably, the Reserves (1,224.00 Cr.) exceed the Borrowings (158.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Refex Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 12.93. This value is within the healthy range. It has increased from 8.40 (Mar 24) to 12.93, marking an increase of 4.53.
• For Diluted EPS (Rs.), as of Mar 25, the value is 12.38. This value is within the healthy range. It has increased from 8.36 (Mar 24) to 12.38, marking an increase of 4.02.
• For Cash EPS (Rs.), as of Mar 25, the value is 14.78. This value is within the healthy range. It has increased from 9.21 (Mar 24) to 14.78, marking an increase of 5.57.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.93. It has increased from 40.25 (Mar 24) to 81.93, marking an increase of 41.68.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 81.93. It has increased from 40.25 (Mar 24) to 81.93, marking an increase of 41.68.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 191.02. It has increased from 119.54 (Mar 24) to 191.02, marking an increase of 71.48.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 20.14. This value is within the healthy range. It has increased from 14.21 (Mar 24) to 20.14, marking an increase of 5.93.
• For PBIT / Share (Rs.), as of Mar 25, the value is 17.62. This value is within the healthy range. It has increased from 13.04 (Mar 24) to 17.62, marking an increase of 4.58.
• For PBT / Share (Rs.), as of Mar 25, the value is 15.48. This value is within the healthy range. It has increased from 10.49 (Mar 24) to 15.48, marking an increase of 4.99.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 12.26. This value is within the healthy range. It has increased from 8.04 (Mar 24) to 12.26, marking an increase of 4.22.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 12.29. This value is within the healthy range. It has increased from 8.11 (Mar 24) to 12.29, marking an increase of 4.18.
• For PBDIT Margin (%), as of Mar 25, the value is 10.54. This value is within the healthy range. It has decreased from 11.88 (Mar 24) to 10.54, marking a decrease of 1.34.
• For PBIT Margin (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 10. It has decreased from 10.90 (Mar 24) to 9.22, marking a decrease of 1.68.
• For PBT Margin (%), as of Mar 25, the value is 8.10. This value is below the healthy minimum of 10. It has decreased from 8.77 (Mar 24) to 8.10, marking a decrease of 0.67.
• For Net Profit Margin (%), as of Mar 25, the value is 6.41. This value is within the healthy range. It has decreased from 6.72 (Mar 24) to 6.41, marking a decrease of 0.31.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.43. This value is below the healthy minimum of 8. It has decreased from 6.78 (Mar 24) to 6.43, marking a decrease of 0.35.
• For Return on Networth / Equity (%), as of Mar 25, the value is 15.00. This value is within the healthy range. It has decreased from 20.16 (Mar 24) to 15.00, marking a decrease of 5.16.
• For Return on Capital Employeed (%), as of Mar 25, the value is 16.22. This value is within the healthy range. It has decreased from 24.96 (Mar 24) to 16.22, marking a decrease of 8.74.
• For Return On Assets (%), as of Mar 25, the value is 8.82. This value is within the healthy range. It has decreased from 11.76 (Mar 24) to 8.82, marking a decrease of 2.94.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has decreased from 0.11 (Mar 24) to 0.08, marking a decrease of 0.03.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.16. This value is within the healthy range. It has decreased from 0.25 (Mar 24) to 0.16, marking a decrease of 0.09.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.90. It has increased from 1.78 (Mar 24) to 1.90, marking an increase of 0.12.
• For Current Ratio (X), as of Mar 25, the value is 3.49. This value exceeds the healthy maximum of 3. It has increased from 2.59 (Mar 24) to 3.49, marking an increase of 0.90.
• For Quick Ratio (X), as of Mar 25, the value is 3.47. This value exceeds the healthy maximum of 2. It has increased from 2.55 (Mar 24) to 3.47, marking an increase of 0.92.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 74.24. This value exceeds the healthy maximum of 8. It has increased from 30.57 (Mar 24) to 74.24, marking an increase of 43.67.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 5.88 (Mar 24) to 0.00, marking a decrease of 5.88.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 5.14 (Mar 24) to 0.00, marking a decrease of 5.14.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 94.12 (Mar 24) to 0.00, marking a decrease of 94.12.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 94.86 (Mar 24) to 0.00, marking a decrease of 94.86.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 9.39. This value is within the healthy range. It has increased from 5.60 (Mar 24) to 9.39, marking an increase of 3.79.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.72. This value is within the healthy range. It has increased from 4.17 (Mar 24) to 6.72, marking an increase of 2.55.
• For Enterprise Value (Cr.), as of Mar 25, the value is 4,698.88. It has increased from 1,642.00 (Mar 24) to 4,698.88, marking an increase of 3,056.88.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.90. This value is within the healthy range. It has increased from 1.19 (Mar 24) to 1.90, marking an increase of 0.71.
• For EV / EBITDA (X), as of Mar 25, the value is 18.06. This value exceeds the healthy maximum of 15. It has increased from 9.99 (Mar 24) to 18.06, marking an increase of 8.07.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 1.98, marking an increase of 0.85.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 94.11 (Mar 24) to 0.00, marking a decrease of 94.11.
• For Price / BV (X), as of Mar 25, the value is 4.61. This value exceeds the healthy maximum of 3. It has increased from 3.35 (Mar 24) to 4.61, marking an increase of 1.26.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.98. This value is within the healthy range. It has increased from 1.13 (Mar 24) to 1.98, marking an increase of 0.85.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness